TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To date, there is no treatment strategies for these patients according to American Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus. Thus, we aim to compare the safety and efficacy of TIPS and conservative treatment (non-selective beta blockers, endoscopic therapy and/or anticoagulation) in patients with PVT and CPTV.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zaibo Jiang
• Treatments: Propranolol; Warfarin

Criteria

Inclusion Criteria:

• All patients diagnosis with portal vein thrombosis and cavernous transformation of portal vein and portal hypertension by contrast enhanced CT or MRI.

• History of variceal bleeding.

• Liver cirrhosis.

• Neutrophilous counts≥ 1.5×109/L, Platelet counts ≥ 50 × 109/L, Hemoglobin≥ 85g/L.

• Albumin ≥2.8 g/dL, total bilirubin <51.3 umol/L; alanine aminotransferase (ALT) and aspartate transaminase（AST）<5 times of upper limit.

• PT(Prothrombin time)-INR(international normalized ratio) < 1.7.

Exclusion Criteria:

• Thrombosis involve superior mesenteric vein, splenic vein, or the whole portal vein system. Not suitable for TIPS (judged by principal investigator).

• Company with malignant tumors in liver or other organs.

• Patients with known severe dysfunction of heart, lung, brain or kidney.

• Active bleeding.

• Not eligible for anticoagulation therapy,non-selective beta blockers or endoscopic therapy.

• Uncontrolled infection.

• Pregnancy and breastfeeding.

• HIV infection.